Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncoclinicas Do Brasil Servicos Medicos's revenue for the
three
months ended in Jun. 2026 was R$1,048 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was R$4,990 Mil.
Oncoclinicas Do Brasil Servicos Medicos's Revenue per Share for the
three
months ended in Jun. 2026 was R$1.61.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was R$6.24.
Warning Sign:
Oncoclinicas Do Brasil Servicos Medicos SA revenue per share has been in decline over the past 3 years.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Oncoclinicas Do Brasil Servicos Medicos Revenue Related Terms
Oncoclinicas Do Brasil Servicos Medicos Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoclinicas Do Brasil Servicos Medicos Revenue Chart
Oncoclinicas Do Brasil Servicos Medicos Annual Data
For the Medical Care Facilities subindustry, Oncoclinicas Do Brasil Servicos Medicos's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoclinicas Do Brasil Servicos Medicos Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oncoclinicas Do Brasil Servicos Medicos's Revenue distribution charts can be found below:
* The bar in red indicates where Oncoclinicas Do Brasil Servicos Medicos's Revenue falls into.
Oncoclinicas Do Brasil Servicos Medicos Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$4,990 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) has a Revenue of R$4,990 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors.
Is Oncoclinicas Do Brasil Servicos Medicos' Revenue too high?
Oncoclinicas Do Brasil Servicos Medicos' current Revenue is R$4,990 Mil. Overall, Oncoclinicas Do Brasil Servicos Medicos has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoclinicas Do Brasil Servicos Medicos' Revenue compare to HCA and THC?
Oncoclinicas Do Brasil Servicos Medicos' Revenue of R$4,990 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. Oncoclinicas Do Brasil Servicos Medicos's current Revenue is R$4,990 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoclinicas Do Brasil Servicos Medicos stock overvalued right now?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) is currently considered Possible Value Trap. The stock's GF Value™ is R$3.39, compared to a current price of R$1.20 — trading 64.6% below its estimated fair value. The current Revenue is R$4,990 Mil. Oncoclinicas Do Brasil Servicos Medicos' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3), the current Revenue is R$4,990 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos stock appears to be undervalued.
The current stock price of R$1.20 is trading 64.6% below its estimated GF Value™ of R$3.39.
GuruFocus considers Oncoclinicas Do Brasil Servicos Medicos to be Possible Value Trap.
Key valuation signals for BSP:ONCO3:
Revenue: R$4,990 Mil
GF Value™: R$3.39 vs. price of R$1.20 (64.6% below fair value)
No single metric tells the full story. See the BSP:ONCO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.
46GF Score
Get the complete analysis for BSP:ONCO3
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:ONCO3 has been successfully added to your 
